These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27058026)

  • 1. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 2. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 3. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Wendtner CM
    Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
    Molica S; Levato L; Mirabelli R
    Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
    Burger JA
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
    [No Abstract]   [Full Text] [Related]  

  • 9. Ibrutinib for Chronic Lymphocytic Leukemia with
    Ahn IE; Tian X; Wiestner A
    N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
    [No Abstract]   [Full Text] [Related]  

  • 10. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
    Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 12. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib: searching for a partner drug.
    Kater AP; Brown JR
    Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
    Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
    Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
    [No Abstract]   [Full Text] [Related]  

  • 16. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
    Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
    Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
    Ysebaert L; Aurran-Schleinitz T; Dartigeas C; Dilhuydy MS; Feugier P; Michallet AS; Tournilhac O; Dupuis J; Sinet P; Albrecht C; Cymbalista F
    Am J Hematol; 2017 Aug; 92(8):E166-E168. PubMed ID: 28439916
    [No Abstract]   [Full Text] [Related]  

  • 18. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
    Barrientos J; Rai K
    Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Goldschmidt N; Rund D
    Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
    Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.